| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6028222 | MALLINCKRODT HOSP | Stable liquid paracetamol compositions, and method for preparing same |
Aug, 2017
(6 years ago) | |
|
US6028222 (Pediatric) | MALLINCKRODT HOSP | Stable liquid paracetamol compositions, and method for preparing same |
Feb, 2018
(6 years ago) | |
| US6992218 | MALLINCKRODT HOSP | Method for obtaining aqueous formulations of oxidation-sensitive active principles |
Jun, 2021
(2 years ago) | |
|
US6992218 (Pediatric) | MALLINCKRODT HOSP | Method for obtaining aqueous formulations of oxidation-sensitive active principles |
Dec, 2021
(2 years ago) | |
| US9610265 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(4 years from now) | |
| US9987238 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(4 years from now) | |
| US10383834 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(4 years from now) | |
|
US9987238 (Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
May, 2029
(5 years from now) | |
|
US9610265 (Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
May, 2029
(5 years from now) | |
| US9399012 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Sep, 2031
(7 years from now) | |
|
US9399012 (Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Mar, 2032
(7 years from now) | |
Ofirmev is owned by Mallinckrodt Hosp.
Ofirmev contains Acetaminophen.
Ofirmev has a total of 11 drug patents out of which 4 drug patents have expired.
Expired drug patents of Ofirmev are:
- US6028222
- US6028222*PED
- US6992218
- US6992218*PED
Ofirmev was authorised for market use on 02 November, 2010.
Ofirmev is available in solution;intravenous dosage forms.
Ofirmev can be used as modified dosing regimen for the management of mild to moderate pain, modified dosing regimen for the management of mild to moderate pain or management of moderate to severe pain as an adjunct to opioid analgesics, modified dosing regimen for the management of moderate to severe pain with adjunctive opioid analgesics.
The generics of Ofirmev are possible to be released after 11 March, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-196) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| New Product(NP) | Nov 02, 2013 |
Drugs and Companies using ACETAMINOPHEN ingredient
Market Authorisation Date: 02 November, 2010
Treatment: Modified dosing regimen for the management of moderate to severe pain with adjunctive opioid analgesics; Modified dosing regimen for the management of mild to moderate pain or management of moderate t...
Dosage: SOLUTION;INTRAVENOUS
OFIRMEV family patents
